Scientific Online Resource System

Scripta Scientifica Medica

Dynamic change of NT- PROBNP in patients with ST-elevation myocardial infarction treated with primary coronary intervention

Javor Kostadinov Kashlov, Veselin Dobrev Valkov, Yordanka Georgieva Doneva, Ivan Donev, Arpine Kirkorova, Galina Arabadzhieva, Lilia Ivanova, Nikolay Conev, Borislav Ivanov, Temenuzhka Radeva, Zhaneta Georgieva

Abstract

In the recent years important biomarkers have  emerged as  tools for diagnosis and risk stratification in cardiovascular diseases. Such markers are B- type natriuretic peptide ( BNP) and N- terminal B- type  natriuretic peptide (NT-proBNP).

Peripheral blood for the serum levels of  NT-proBNP was taken from patients with STEMI before PCI and 24-48hours after the onset of the symptoms of myocardial infarction. Three of the samples  from all 53 turned out to be positive to NT - proBNP  concentration on Day 0. On day 1 there was   a significant  elevation of the positive samples 11 from 53 patients ( 20,7%) ( p = 0,01). All  patients with STEMI and elevated serum levels of NT- proBNP  have left ventricular ejection fraction <50%. 

 Our results imply that  NT -proBNP level and its increase in the serum  may be used as a biomarker for the severity of the ischemic heart disease.


Keywords

myocardial infarction; ejection fraction; NT-proBNP;percutaneous coronary intervention

Full Text


References

Gaziano, T., et al., Cardiovascular Disease, in Disease Control Priorities in Developing Countries, D.T. Jamison, et al., Editors. 2006: Washington (DC).

Andersen, H.R., et al., A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med, 2003. 349(8): p. 733-42.

Boden, W.E., K. Eagle, and C.B. Granger, Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. J Am Coll Cardiol, 2007. 50(10): p. 917-29.

Keeley, E.C., J.A. Boura, and C.L. Grines, Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet, 2003. 361(9351): p. 13-20.

Morita, E., et al., Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation, 1993. 88(1): p. 82-91.

Swedberg, K., et al., Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J, 2005. 26(11): p. 1115-40.

Nagaya, N., et al., Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J, 1998. 135(1): p. 21-8.

Talwar, S., et al., Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J, 2000. 21(18): p. 1514-21.

Groenning, B.A., et al., Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J, 2002. 143(5): p. 923-9.

Galvani, M., et al., N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation, 2004. 110(2): p. 128-34.

Bazzino, O., et al., Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J, 2004. 25(10): p. 859-66.

Kim, H., et al., Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ J, 2006. 70(11): p. 1379-84.

Szadkowska, I., et al., The relationship between early recanalization and serum NT-proBNP levels in patients with a first ST-segment elevation myocardial infarction treated with primary coronary angioplasty. Acta Cardiol, 2007. 62(5): p. 479-84.

Kashlov, J.K., et al., Serum levels of RIPK3 and troponin I as potential biomarkers for predicting impaired left ventricular function in patients with myocardial infarction with ST segment elevation and normal troponin I levels prior percutaneous coronary intervention. Biosci Trends, 2016. 10(4): p. 294-9.

Linkermann, A. and D.R. Green, Necroptosis. N Engl J Med, 2014. 370(5): p. 455-65.

Zhao, H., et al., Role of necroptosis in the pathogenesis of solid organ injury. Cell Death Dis, 2015. 6: p. e1975.




DOI: http://dx.doi.org/10.14748/ssm.v48i4.1851
Array
About The Authors

Javor Kostadinov Kashlov
Medical University ,Varna
Bulgaria

Department of Propedeutics of Internal Medicine-physician

Veselin Dobrev Valkov
Medical University of Varna
Bulgaria

Department of Cardiology- physician

Yordanka Georgieva Doneva
Medical University of Varna
Bulgaria

Department of Propedeutics of Internal Medicine-physician

Ivan Donev
Medical University of Varna
Bulgaria

Department of Propedeutics of Internal Medicine

Arpine Kirkorova
Medical University of Varna
Bulgaria

Department of Propedeutics of Internal Medicine

Galina Arabadzhieva
St. Marina University Hospital
Bulgaria

Department of Cardiology

Lilia Ivanova
Medical University of Varna
Bulgaria

Department of Microbiology and Virology

Nikolay Conev
Medical University of Varna
Bulgaria

Department of Propedeutics of Internal Medicine

Borislav Ivanov
Medical University of Varna
Bulgaria

Department of Clinical Medical Sciences

Temenuzhka Radeva
St. Marina University Hospital
Bulgaria

Department of Radiation Oncology and Imaging Diagnostic

Zhaneta Georgieva
Medical University of Varna
Bulgaria

Department of Propedeutics of Internal Medicine

Font Size


|